查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1387496

皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场报告：2030 年趋势、预测与竞争分析

Cutaneous Bcell Lymphoma Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

皮肤 B 细胞淋巴瘤 (CBCL) 治疗趋势与预测

预计 2024 年至 2030 年，全球皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场将以 2.3% 的年复合成长率成长。该市场的主要驱动力是越来越多地采用先进的标靶治疗、增加临床证据的经验使用以及增加用于治疗皮肤 B 细胞淋巴瘤 (CBCL) 的新产品开发的研发投资。全球皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场前景看好，医院和专科诊所市场蕴含商机。

皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场洞察

Lucintel 预测，由于化疗对晚期病例的有效性以及对不同疾病阶段的适应性，化疗将在预测期内达到最高成长。

预计北美地区在预测期内将出现最高的成长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球皮肤B细胞淋巴瘤（CBCL）治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球皮肤B细胞淋巴瘤（CBCL）治疗市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场
    • 放射线治疗
    • 化疗
    • 单株抗体
    • 其他的
  • 全球皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场（按最终用途）
    • 医院
    • 专科诊所
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场（按地区）
  • 北美皮肤B细胞淋巴瘤（CBCL）治疗市场
  • 欧洲皮肤B细胞淋巴瘤（CBCL）治疗市场
  • 亚太皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场
  • 其他地区皮肤B细胞淋巴瘤（CBCL）治疗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场成长机会
    • 全球皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场成长机会（按最终用途）
    • 全球皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场成长机会（按地区）
  • 全球皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场的产能
    • 全球皮肤 B 细胞淋巴瘤 (CBCL) 治疗市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Kite Pharma
  • Genentech
  • Novartis
  • Epizyme
  • NanoString Technologies
  • Amgen
  • Johnson & Johnson Services
简介目录

Cutaneous Bcell Lymphoma Treatment Trends and Forecast

The future of the global cutaneous Bcell lymphoma treatment market looks promising with opportunities in the hospitals, and speciality clinics markets. The global cutaneous Bcell lymphoma treatment market is expected to grow with a CAGR of 2.3% from 2024 to 2030. The major drivers for this market are growing adoption of advanced and targeted therapies, increasing usage of clinical evidence demonstrating, as well as, rising investments in research and development to develop novel products to cure cutaneous Bcell lymphoma.

A more than 150-page report is developed to help in your business decisions.

Cutaneous Bcell Lymphoma Treatment by Segment

The study includes a forecast for the global cutaneous Bcell lymphoma treatment by type, end use, and region.

Cutaneous Bcell Lymphoma Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Radiation Therapy
  • Chemotherapy
  • Monoclonal Antibodies
  • Others

Cutaneous Bcell Lymphoma Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Speciality Clinics
  • Others

Cutaneous Bcell Lymphoma Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cutaneous Bcell Lymphoma Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cutaneous Bcell lymphoma treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cutaneous Bcell lymphoma treatment companies profiled in this report include-

  • Kite Pharma
  • Genentech
  • Novartis
  • Epizyme
  • Nanostring Technologies
  • Amgen
  • Johnson & Johnson Services

Cutaneous Bcell Lymphoma Treatment Market Insights

Lucintel forecasts that chemotherapy is expected to witness highest growth over the forecast period because of its effectiveness in advanced case and adaptability to different disease stages.

North America is expected to witness highest growth over the forecast period.

Features of the Global Cutaneous Bcell Lymphoma Treatment Market

Market Size Estimates: Cutaneous Bcell lymphoma treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cutaneous Bcell lymphoma treatment market size by type, end use, and region in terms of value ($B).

Regional Analysis: Cutaneous Bcell lymphoma treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, end use, and regions for the cutaneous Bcell lymphoma treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cutaneous Bcell lymphoma treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for cutaneous Bcell lymphoma treatment market?

Answer: The global cutaneous Bcell lymphoma treatment market is expected to grow with a CAGR of 2.3% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the cutaneous Bcell lymphoma treatment market?

Answer: The major drivers for this market are growing adoption of advanced and targeted therapies, increasing usage of clinical evidence demonstrating, as well as, rising investments in research and development to develop novel products to cure cutaneous Bcell lymphoma.

Q3. What are the major segments for cutaneous Bcell lymphoma treatment market?

Answer: The future of the global cutaneous Bcell lymphoma treatment market looks promising with opportunities in the hospitals, and speciality clinics markets.

Q4. Who are the key cutaneous Bcell lymphoma treatment market companies?

Answer: Some of the key cutaneous Bcell lymphoma treatment companies are as follows:

  • Kite Pharma
  • Genentech
  • Novartis
  • Epizyme
  • Nanostring Technologies
  • Amgen
  • Johnson & Johnson Services

Q5. Which cutaneous Bcell lymphoma treatment market segment will be the largest in future?

Answer: Lucintel forecasts that chemotherapy is expected to witness highest growth over the forecast period because of its effectiveness in advanced case and adaptability to different disease stages.

Q6. In cutaneous Bcell lymphoma treatment market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cutaneous Bcell lymphoma treatment market by type (radiation therapy, chemotherapy, monoclonal antibodies, and others), end use (hospitals, speciality clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cutaneous Bcell Lymphoma Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cutaneous Bcell Lymphoma Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cutaneous Bcell Lymphoma Treatment Market by Type
    • 3.3.1: Radiation Therapy
    • 3.3.2: Chemotherapy
    • 3.3.3: Monoclonal Antibodies
    • 3.3.4: Others
  • 3.4: Global Cutaneous Bcell Lymphoma Treatment Market by End Use
    • 3.4.1: Hospitals
    • 3.4.2: Speciality Clinics
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cutaneous Bcell Lymphoma Treatment Market by Region
  • 4.2: North American Cutaneous Bcell Lymphoma Treatment Market
    • 4.2.2: North American Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
  • 4.3: European Cutaneous Bcell Lymphoma Treatment Market
    • 4.3.1: European Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
    • 4.3.2: European Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
  • 4.4: APAC Cutaneous Bcell Lymphoma Treatment Market
    • 4.4.1: APAC Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
    • 4.4.2: APAC Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
  • 4.5: ROW Cutaneous Bcell Lymphoma Treatment Market
    • 4.5.1: ROW Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
    • 4.5.2: ROW Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by End Use
    • 6.1.3: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by Region
  • 6.2: Emerging Trends in the Global Cutaneous Bcell Lymphoma Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cutaneous Bcell Lymphoma Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cutaneous Bcell Lymphoma Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Kite Pharma
  • 7.2: Genentech
  • 7.3: Novartis
  • 7.4: Epizyme
  • 7.5: NanoString Technologies
  • 7.6: Amgen
  • 7.7: Johnson & Johnson Services